2016 Scientific Sessions Sol Sherry Distinguished Lecturer in ThrombosisHighlights
Thrombotic Stroke: Neuroprotective Therapy by Recombinant-Activated Protein C
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
APC (activated protein C), derived from the plasma protease zymogen, is antithrombotic and anti-inflammatory. In preclinical injury models, recombinant APC provides neuroprotection for multiple injuries, including ischemic stroke. APC acts directly on brain endothelial cells and neurons by initiating cell signaling that requires multiple receptors. Two or more major APC receptors mediate APC’s neuroprotective cell signaling. When bound to endothelial cell protein C receptor, APC can cleave protease-activated receptor 1, causing biased cytoprotective signaling that reduces ischemia-induced injury. Pharmacological APC alleviates bleeding induced by tissue-type plasminogen activator in murine ischemic stroke studies. Remarkably, APC’s signaling promotes neurogenesis. The signaling-selective recombinant variant of APC, 3K3A-APC, was engineered to lack most of the APC’s anticoagulant activity but retain APC’s cell signaling actions. Recombinant 3K3A-APC is in ongoing National Institutes of Health (NIH)–funded clinical trials for ischemic stroke.
- Received August 23, 2016.
- Accepted September 21, 2016.
- © 2016 American Heart Association, Inc.